Overview

Study of HL-085 in NRAS Mutant Advanced Melanoma

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Shanghai Kechow Pharma, Inc.